卡维地洛治疗慢性充血性心力衰竭68例

目的 观察卡维地洛治疗慢性心力衰竭（CHF）的安全性及临床疗效。方法选择慢性CHF患者68例，随机分为两组：对照组（34例）给予洋地黄制剂、利尿剂、血管扩张剂、血管紧张素转化酶抑制剂；卡维地洛组（34例）在常规治疗基础上加用卡维地洛（25mg，2次／d，共用90d）治疗。结果卡维地洛组心功能改善的临床显效率（47．8％）和总有效率（91．3％）均较对照组（26．1％和65．2％）显著提高（P〈0．01），且无明显不良反应出现。卡维地洛组治疗后与治疗前相比，心率、血压、左室射血分数、左室舒张末期容积、左室收缩末期容积均有显著改善（P〈0．01或P〈0．05）。结论CHF患者在常规治疗的基础上加用卡维地洛可进一步提高疗效，改善心功能，安全有效。

Efficacy analysis of carvedilol in treatment of chronic heart failure

Objective To observe the clinical therapeutic effect and safety of carvedilol in the treatment of chronic heart failure. Methods Sixty - eight cases of patients with chronic CHF were randomly divided into two groups： one group was received routine treatment （ digitalis, diuretics, vasodilator, ACEI）, and another group was received carvedilor （ 25 mg, hid ×90 d）as well as routine treatment. Results The treatment efficiency in carvedilol group and control group were respectively 91.3% and 65.2% with signifieent difference between two groups, P 〈 0.01 ）. No adverse reactions associated with carvedilol were observed. The improvements of HR, BP, LVEF, EDV, ESV after treatment in carvedilol group were significant （P 〈 0. 01 or P 〈 0. 05 ）. Conclusions Adding earvedilol based on the routine therapy can improve the effect and the heart function. Carvedilol is a safe and effective drug.